Descrizione del progetto
Una tecnologia proprietaria protegge contro lo spostamento del catetere endovenoso
Ogni anno vengono utilizzati quasi 3,8 miliardi di cateteri endovenosi, rendendo la terapia che se ne avvale il trattamento invasivo più eseguito in Europa e negli Stati Uniti. Tuttavia, incidenti legati allo spostamento del catetere comportano costi sanitari supplementari ed espongono il personale infermieristico a rischi inutili tra cui farmaci tossici e sangue contaminato. Per affrontare tale problema, Il progetto ReLink, finanziato dall’UE, ha sviluppato un connettore di sicurezza proprietario destinato a proteggere i pazienti e il personale infermieristico da questi problemi. Il progetto lavorerà verso uno sviluppo ulteriore del prodotto accanto all’esecuzione delle normative necessarie, della proprietà intellettuale e delle attività di collegamento in rete per portarlo dalla fase prototipale attuale sul mercato.
Obiettivo
Intravenous (IV) therapy is the channelling of medicine and blood directly into a patient’s venous system using a plastic tube. With 3.8 billion tubes used per year, it is the most performed invasive treatment in Europe and USA. However, up to 36% of all these treatments are interrupted by an accidental pull to the tube, costing healthcare an annual €28.3 billion. When this happens, the patient will get hurt and blood and medicine will be spilled. It takes a nurse on average 30 minutes to tend to the patient, clean the spill and reinstate therapy. And when doing so, the nurse puts him or herself at risk for being exposed to contaminated blood and toxic medication such as chemotherapy. There global nursing shortage will worsen with population ageing, IV dislodgement does not help this situation. What can help is the ReLink safety connector. ReLink is an award-winning, patented technology which is low cost to produce, intuitive to use, and have the potential to create a new annual market worth €11.4 billion in Europe and USA. The objective for the proposed project is to grow ReLink from its current prototype phase to a market ready product. This involves product development to frozen design (WP 1), regulatory activities to secure clinical evidence, ISO certificate, CE mark and apply for FDA approval (WP 2), intellectual property related activities (WP 3), as well as market surveillance and networking to secure the supply chain, prepare for post-project investments and support from future customers (WP 4) and project management and growing the team (WP 5). Tada Group’s business model is to focus on R&D and marketing. Our core competence is need based product development and evidence based medtech marketing. Production and sales will be done by strategic partners, thus keeping cost of goods low as sales increase. ReLink prevents dislodgement, we will reshape the IV landscape and save lives. Will you join our quest? Join Tada!
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-EIC-SMEInst-2018-2020-3
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
111 39 Stockholm
Svezia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.